Finanzas de Stryker Corp (SYK)SYKStryker Corp

Stryker Corporation (SYK) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Medical, accounting for 17.0% of total sales, equivalent to $1.12B. Other significant revenue streams include Trauma and Extremities and Endoscopy. Understanding this composition is critical for investors evaluating how SYK navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, Stryker Corporation maintains a gross margin of 65.78%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 27.17%, while the net margin is 19.37%. These profitability ratios, combined with a Return on Equity (ROE) of 16.51%, provide a clear picture of how effectively SYK converts its operational activities into shareholder value.

In the context of the broader market, SYK competes directly with industry leaders such as ISRG and MDT. With a market capitalization of $126.84B, it holds a significant position in the sector. When comparing efficiency, SYK's gross margin of 65.78% stands against ISRG's 67.78% and MDT's 61.97%. Such benchmarking helps identify whether Stryker Corporation is trading at a premium or discount relative to its financial performance.

Stryker reported Q2 2026 sales of $6.59 billion, a 9.4% year-over-year increase, and an adjusted EPS of $3.69, exceeding estimates by 5.8%. The gross margin improved to 65.78% in Q2 2026, indicating strong operational efficiency.